47 related articles for article (PubMed ID: 15941391)
21. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
22. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.
Adachi N; Suzuki H; Iiizumi S; Koyama H
J Biol Chem; 2003 Sep; 278(38):35897-902. PubMed ID: 12842886
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds.
van Hille B; Clerc X; Creighton AM; Hill BT
Br J Cancer; 1999 Nov; 81(5):800-7. PubMed ID: 10555749
[TBL] [Abstract][Full Text] [Related]
24. The Escherichia coli RecA protein complements recombination defective phenotype of the Saccharomyces cerevisiae rad52 mutant cells.
Dudás A; Marková E; Vlasáková D; Kolman A; Bartosová Z; Brozmanová J; Chovanec M
Yeast; 2003 Apr; 20(5):389-96. PubMed ID: 12673622
[TBL] [Abstract][Full Text] [Related]
25. Evidence for a role of vertebrate Rad52 in the repair of topoisomerase II-mediated DNA damage.
Adachi N; Iiizumi S; Koyama H
DNA Cell Biol; 2005 Jun; 24(6):388-93. PubMed ID: 15941391
[TBL] [Abstract][Full Text] [Related]
26. Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA.
Morimoto S; Tsuda M; Bunch H; Sasanuma H; Austin C; Takeda S
Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31671674
[TBL] [Abstract][Full Text] [Related]
27. [DNA homologous recombination repair in mammalian cells].
Popławski T; Błasiak J
Postepy Biochem; 2006; 52(2):180-93. PubMed ID: 17078508
[TBL] [Abstract][Full Text] [Related]
28. Homologous DNA recombination in vertebrate cells.
Sonoda E; Takata M; Yamashita YM; Morrison C; Takeda S
Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8388-94. PubMed ID: 11459980
[TBL] [Abstract][Full Text] [Related]
29. Type II topoisomerases--inhibitors, repair mechanisms and mutations.
Heisig P
Mutagenesis; 2009 Nov; 24(6):465-9. PubMed ID: 19762349
[TBL] [Abstract][Full Text] [Related]
30. DNA double-strand break repair by homologous recombination.
van den Bosch M; Lohman PH; Pastink A
Biol Chem; 2002 Jun; 383(6):873-92. PubMed ID: 12222678
[TBL] [Abstract][Full Text] [Related]
31. Role of nucleotide excision repair proteins in response to DNA damage induced by topoisomerase II inhibitors.
Rocha JC; Busatto FF; Guecheva TN; Saffi J
Mutat Res Rev Mutat Res; 2016; 768():68-77. PubMed ID: 27234564
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms to Repair Stalled Topoisomerase II-DNA Covalent Complexes.
Swan RL; Cowell IG; Austin CA
Mol Pharmacol; 2022 Jan; 101(1):24-32. PubMed ID: 34689119
[TBL] [Abstract][Full Text] [Related]
33. Dna repair: Rad52 - the means to an end.
Hiom K
Curr Biol; 1999 Jun; 9(12):R446-8. PubMed ID: 10375523
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms of topoisomerase 2 DNA-protein crosslink resolution.
Riccio AA; Schellenberg MJ; Williams RS
Cell Mol Life Sci; 2020 Jan; 77(1):81-91. PubMed ID: 31728578
[TBL] [Abstract][Full Text] [Related]
35. Corrupting the DNA damage response: a critical role for Rad52 in tumor cell survival.
Lieberman R; You M
Aging (Albany NY); 2017 Jul; 9(7):1647-1659. PubMed ID: 28722656
[TBL] [Abstract][Full Text] [Related]
36. Genetic analysis of homologous DNA recombination in vertebrate somatic cells.
Morrison C; Takeda S
Int J Biochem Cell Biol; 2000 Aug; 32(8):817-31. PubMed ID: 10940640
[TBL] [Abstract][Full Text] [Related]
37. Broken by the Cut: A Journey into the Role of Topoisomerase II in DNA Fragility.
Atkin ND; Raimer HM; Wang YH
Genes (Basel); 2019 Oct; 10(10):. PubMed ID: 31614754
[TBL] [Abstract][Full Text] [Related]
38. Targeting DNA topoisomerase II in cancer chemotherapy.
Nitiss JL
Nat Rev Cancer; 2009 May; 9(5):338-50. PubMed ID: 19377506
[TBL] [Abstract][Full Text] [Related]
39. A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex).
Xu H; Hurley LH
Bioorg Med Chem Lett; 2022 Dec; 77():129016. PubMed ID: 36195286
[TBL] [Abstract][Full Text] [Related]
40. The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy.
Matias-Barrios VM; Dong X
Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
